{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Kimia Biosciences Ltd
Kimia Biosciences Ltd is Rated Sell
Kimia Biosciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 15 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Kimia Biosciences Ltd is Rated Sell
Kimia Biosciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 15 February 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock's current position as of 19 February 2026, providing investors with the latest insights into the company’s performance and outlook.
Are Kimia Biosciences Ltd latest results good or bad?
Kimia Biosciences Ltd's latest results show strong revenue growth with net sales up 44.19% sequentially, but profitability has declined significantly, with net profit down 36.65% year-on-year and operating margins at their lowest. Overall, while revenue is increasing, the company faces challenges in maintaining profitability and operational efficiency.
Kimia Biosciences Ltd is Rated Strong Sell
Kimia Biosciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 September 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Kimia Biosciences Ltd is Rated Strong Sell
Kimia Biosciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 Sep 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 28 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Kimia Biosciences Ltd is Rated Strong Sell
Kimia Biosciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 September 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 05 January 2026, providing investors with the latest insights into the company’s performance and outlook.
Kimia Biosciences Ltd is Rated Strong Sell
Kimia Biosciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 Sep 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 December 2025, providing investors with an up-to-date view of the company's fundamentals, returns, and market performance.
Kimia Bioscien. Sees Revision in Market Evaluation Amidst Challenging Fundamentals
Kimia Bioscien., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting shifts in its fundamental and technical outlook. This adjustment follows a detailed reassessment of the company’s quality, valuation, financial trends, and technical indicators, highlighting ongoing challenges in its operational and market performance.
Kimia Biosciences Falls to 52-Week Low of Rs.26.09 Amidst Continued Downtrend
Kimia Biosciences touched a fresh 52-week low of Rs.26.09 today, marking a significant decline amid a sustained downward trend. The stock has experienced notable volatility and underperformance relative to its sector and benchmark indices over the past year.
Kimia Biosciences Falls to 52-Week Low of Rs.27.2 Amidst Continued Downtrend
Kimia Biosciences has reached a new 52-week low of Rs.27.2, marking a significant decline in its stock price amid a sustained downward trend over recent days. The pharmaceutical and biotechnology company’s shares have underperformed relative to its sector and broader market indices, reflecting ongoing pressures on its valuation and financial metrics.
Kimia Biosciences Falls to 52-Week Low of Rs.27.2 Amidst Continued Downtrend
Kimia Biosciences has reached a new 52-week low of Rs.27.2 today, marking a significant decline in its stock price amid a sustained downward trend over recent sessions. The pharmaceutical and biotechnology company’s shares have underperformed both its sector and broader market indices, reflecting ongoing pressures on its valuation and financial metrics.
Kimia Biosciences Falls to 52-Week Low of Rs.28.4 Amidst Continued Downtrend
Kimia Biosciences has reached a new 52-week low of Rs.28.4 today, marking a significant decline in its stock price amid ongoing downward momentum. The stock has experienced notable volatility and underperformance relative to its sector and benchmark indices.
Why is Kimia Bioscien. falling/rising?
On 21-Nov, Kimia Biosciences Ltd witnessed a significant decline in its share price, falling by 5.78% to close at ₹32.13. This drop reflects ongoing concerns about the company's weak long-term fundamentals, high debt levels, and underwhelming recent financial performance, which have collectively weighed on investor sentiment.
Kimia Biosciences Q2 FY26: Margin Compression Overshadows Revenue Growth
Kimia Biosciences Ltd., a Gurgaon-based pharmaceutical company specialising in bulk drug manufacturing, reported net profit of ₹1.02 crores for Q2 FY26, marking a sequential increase of 70.00% from ₹0.60 crores in Q1 FY26. However, year-on-year comparison reveals a concerning decline of 36.65% from ₹1.61 crores in Q2 FY25. The company's stock, trading at ₹34.00 with a modest market capitalisation of ₹159 crores, has struggled significantly, declining 27.66% over the past year whilst the broader Sensex gained 9.48%.
Kimia Biosciences Financial Trend Shifts to Flat Amid Mixed Quarterly Performance
Kimia Biosciences, a player in the Pharmaceuticals & Biotechnology sector, has experienced a notable adjustment in its financial trend parameter, moving from a negative to a flat evaluation in the quarter ending September 2025. This shift reflects a stabilisation in key financial metrics despite ongoing challenges in profitability and margin performance.
Is Kimia Bioscien. overvalued or undervalued?
As of November 17, 2025, Kimia Bioscien. is considered an attractive investment opportunity due to its undervaluation compared to peers, with a PE Ratio of 19.11, a low PEG Ratio of 0.11, and strong ROE of 82.13%, despite a year-to-date stock performance of -27.62%.
How has been the historical performance of Kimia Bioscien.?
Kimia Bioscien's historical performance has shown fluctuations, with net sales declining from a peak of 132.71 Cr in Mar'21 to 118.92 Cr in Mar'25. However, the latest fiscal year marked a recovery, with operating profit rising to 21.57 Cr and profit after tax reaching 9.61 Cr, alongside an increase in total assets.
How has been the historical performance of Kimia Bioscien.?
Kimia Bioscien has shown a fluctuating financial performance, with net sales declining from 132.71 Cr in March 2021 to 118.92 Cr in March 2025, but recovering in profitability with a profit after tax of 9.61 Cr in March 2025, reversing previous losses. The company also improved its cash flow from operating activities to 21.00 Cr in the latest fiscal year.
Why is Kimia Bioscien. falling/rising?
As of 14-Nov, Kimia Biosciences Ltd's stock price has risen to Rs 34.98, reflecting a 9.31% increase, with strong short-term performance despite long-term challenges. The stock's recent profit growth and increased investor participation indicate a potential positive shift in sentiment, despite high debt levels.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
